Cargando…
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide speci...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968866/ https://www.ncbi.nlm.nih.gov/pubmed/8123488 |
_version_ | 1782134834154438656 |
---|---|
author | Pasanen, P. A. Eskelinen, M. Partanen, K. Pikkarainen, P. Penttilä, I. Alhava, E. |
author_facet | Pasanen, P. A. Eskelinen, M. Partanen, K. Pikkarainen, P. Penttilä, I. Alhava, E. |
author_sort | Pasanen, P. A. |
collection | PubMed |
description | The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide specific antigen (TPS), in the diagnosis of pancreatic cancer. The serum values were measured in a prospective series of patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a cancer of the papilla of Vater in this series. Our results showed that CA 50 (P < 0.001) and TPA (P < 0.01) were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242 (P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not (P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DSI) was developed. The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (-1.21). The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of 82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and TPA. |
format | Text |
id | pubmed-1968866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19688662009-09-10 A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Pasanen, P. A. Eskelinen, M. Partanen, K. Pikkarainen, P. Penttilä, I. Alhava, E. Br J Cancer Research Article The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide specific antigen (TPS), in the diagnosis of pancreatic cancer. The serum values were measured in a prospective series of patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a cancer of the papilla of Vater in this series. Our results showed that CA 50 (P < 0.001) and TPA (P < 0.01) were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242 (P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not (P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DSI) was developed. The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (-1.21). The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of 82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and TPA. Nature Publishing Group 1994-03 /pmc/articles/PMC1968866/ /pubmed/8123488 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Pasanen, P. A. Eskelinen, M. Partanen, K. Pikkarainen, P. Penttilä, I. Alhava, E. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title | A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title_full | A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title_fullStr | A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title_full_unstemmed | A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title_short | A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
title_sort | prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968866/ https://www.ncbi.nlm.nih.gov/pubmed/8123488 |
work_keys_str_mv | AT pasanenpa aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT eskelinenm aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT partanenk aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT pikkarainenp aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT penttilai aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT alhavae aprospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT pasanenpa prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT eskelinenm prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT partanenk prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT pikkarainenp prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT penttilai prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore AT alhavae prospectivestudyofserumtumourmarkerscarcinoembryonicantigencarbohydrateantigens50and242tissuepolypeptideantigenandtissuepolypeptidespecificantigeninthediagnosisofpancreaticcancerwithspecialreferencetomultivariatediagnosticscore |